33 Participants Needed

Epcoritamab + Tazemetostat for Follicular Lymphoma

Recruiting at 1 trial location
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This phase II trial tests the safety, side effects and effectiveness of epcoritamab and tazemetostat in treating patients with grade I-IIIa follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Epcoritamab is a bispecific monoclonal antibody that binds to two different antigens on the surface of cancer cells that may help the body's immune system attack the cancer and may interfere with the ability of the cancer cells to grow and spread. Tazemetostat, a EZH2 inhibitor, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving epcoritamab and tazemetostat may be safe, tolerable and/or effective in treating patients with relapsed or refractory grade I-IIIa follicular lymphoma.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, you cannot take certain medications like strong and moderate CYP3A4 inducers or inhibitors within 14 days before starting the trial. It's best to discuss your current medications with the trial team to see if any adjustments are needed.

What makes the drug combination of Epcoritamab and Tazemetostat unique for treating follicular lymphoma?

The combination of Epcoritamab and Tazemetostat is unique because it targets follicular lymphoma using two different mechanisms: Epcoritamab is a bispecific antibody that engages the immune system to attack cancer cells, while Tazemetostat inhibits EZH2, a protein that can promote cancer growth. This dual approach may offer a novel treatment option compared to existing therapies.12345

Who Is on the Research Team?

Dr. Swetha Kambhampati, MD | Duarte, CA ...

Swetha Kambhampati, MD

Principal Investigator

City of Hope Medical Center

Are You a Good Fit for This Trial?

This trial is for patients with grade I-IIIa follicular lymphoma that has either returned after treatment or hasn't responded to past treatments. Specific eligibility details are not provided, but typically participants must meet certain health standards and have a confirmed diagnosis.

Inclusion Criteria

Documented informed consent of the participant and/or legally authorized representative
My lymphoma has returned or didn't respond after my first treatment.
My platelet count is at least 50,000, even if I needed a transfusion.
See 18 more

Exclusion Criteria

Concurrent enrollment in another therapeutic investigational study
I have not taken bispecific antibodies or tazemetostat before.
I am not on immunosuppressive drugs, except for prednisolone or its equivalent up to 20 mg daily.
See 18 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive tazemetostat orally twice daily and epcoritamab subcutaneously on specified days of each cycle. Cycles repeat every 28 days for up to 13 cycles.

Up to 13 months
4 visits per cycle (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment completion, with follow-up visits at 30 and 60 days, then for up to 2 years.

Up to 2 years
Multiple visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Epcoritamab
  • Tazemetostat
Trial Overview The trial is testing the combination of epcoritamab, a bispecific antibody targeting cancer cell antigens, and tazemetostat, an enzyme inhibitor aimed at stopping cancer growth. This phase II study evaluates their safety and effectiveness in treating relapsed or refractory lymphoma.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Treatment (epcoritamab, tazemetostat)Experimental Treatment6 Interventions

Epcoritamab is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Epkinly for:
🇪🇺
Approved in European Union as Tepkinly for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

City of Hope Medical Center

Lead Sponsor

Trials
614
Recruited
1,924,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Published Research Related to This Trial

The proposed phase III trial will evaluate the efficacy of letrozole as a maintenance therapy in 540 patients with newly diagnosed advanced epithelial ovarian cancer, aiming to improve progression-free survival (PFS) while minimizing toxicity and enhancing quality of life.
Letrozole, a potent aromatase inhibitor previously used in breast cancer treatment, is expected to show significant benefits in EOC patients, with a projected median PFS of 25.7 months compared to 18 months for the placebo group.
Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.McLaughlin, PMJ., Klar, M., Zwimpfer, TA., et al.[2022]
Third-generation aromatase inhibitors (like anastrozole, letrozole, and exemestane) are effective first-line treatments for postmenopausal breast cancer patients, showing comparable efficacy and safety to the traditional treatment, tamoxifen.
Recent randomized clinical trials indicate that these aromatase inhibitors are well-tolerated and may offer advantages over tamoxifen, with ongoing studies exploring their use in both adjuvant settings and potentially in premenopausal women.
Recent advances in aromatase inhibitor therapy for breast cancer.Assikis, VJ., Buzdar, A.[2019]
Three new third-generation aromatase inhibitors (anastrozole, letrozole, and vorozole) have shown superior efficacy and tolerability compared to previous treatments for post-menopausal women with metastatic breast cancer after tamoxifen therapy, based on phase III trials.
Letrozole is significantly more effective than megestrol acetate, while all three inhibitors are better tolerated than progestin treatments, particularly regarding weight gain, marking a clear advancement in second-line hormonal therapies.
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.Hamilton, A., Piccart, M.[2020]

Citations

Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial. [2022]
Recent advances in aromatase inhibitor therapy for breast cancer. [2019]
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. [2020]
Clinical differences among the aromatase inhibitors. [2007]
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security